Arcus Biosciences
RCUS
64 hedge funds and large institutions have $323M invested in Arcus Biosciences in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 11 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
11% more capital invested
Capital invested by funds: $290M → $323M (+$32.7M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2.57% less ownership
Funds ownership: 60.56% → 57.99% (-2.6%)
4% less funds holding
Funds holding: 67 → 64 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.33M |
| 2 |
BlackRock
New York
|
+$1.19M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$518K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$459K |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
+$340K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$7.18M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.17M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.53M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.38M |
| 5 |
ACM
Aisling Capital Management
New York
|
-$2.21M |
RCUS Hedge Fund Activity: Q1 2019 in Review
64 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2019, worth a combined $323M — up 11% from $290M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RCUS and 8 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 23 added.
The largest buyer was BVF Inc, adding an estimated $4.33M. The largest seller was Foresite Capital Management III, cutting an estimated $7.18M.
- 64 institutional investors held Arcus Biosciences (RCUS) as of Q1 2019, down from 67 in Q4 2018.
- Funds reported $323M of Arcus Biosciences stock for Q1 2019, up 11% quarter-over-quarter.
- 8 funds opened new Arcus Biosciences positions in Q1 2019 and 11 closed out, a net change of -3 holders.
- The largest Arcus Biosciences buyer in Q1 2019 was BVF Inc, an estimated $4.33M added.
- The largest Arcus Biosciences seller in Q1 2019 was Foresite Capital Management III, an estimated $7.18M sold.
Based on aggregated 13F filings for Q1 2019.